Ensign Peak Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ensign Peak Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-194,933	Closed	-$2.95M	–	1757
2023 Q4	$2.95M	Hold	194,933	–	–	0.01%	762
2023 Q3	$3.91M	Hold	194,933	–	–	0.01%	637
2023 Q2	$5.5M	Hold	194,933	–	–	0.01%	558
2023 Q1	$3.35M	Hold	194,933	–	–	0.01%	675
2022 Q4	$3.93M	Buy	194,933 +43,080	+28%	+$927K	0.01%	617
2022 Q3	$3.29M	Buy	151,853 +68,327	+82%	+$1.87M	0.01%	635
2022 Q2	$2.35M	Hold	83,526	–	–	0.01%	747
2022 Q1	$3.85M	Hold	83,526	–	–	0.01%	661
2021 Q4	$7.02M	Buy	83,526 +48,946	+142%	+$3.79M	0.01%	566
2021 Q3	$2.3M	Sell	34,580 -30,000	-46%	-$1.73M	﹤0.01%	1034
2021 Q2	$3.44M	Buy	64,580 +56,280	+678%	+$3.01M	0.01%	813
2021 Q1	$360K	Hold	8,300	–	–	﹤0.01%	1649
2020 Q4	$431K	Buy	+8,300	New	+$374K	﹤0.01%	1627

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ensign Peak Advisors's ZNTL Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2024, closing a stake of 194,933 shares — an estimated $2.95M sold.

Ensign Peak Advisors first reported a position in ZNTL in Q4 2020 and held it in 13 quarters. The position peaked at $7.02M in Q4 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

Ensign Peak Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Ensign Peak Advisors sold 194,933 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $2.95M.
Ensign Peak Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 13 quarters.
Ensign Peak Advisors's Zentalis Pharmaceuticals position peaked at $7.02M in Q4 2021.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.